


96/23 PH

# 22

5/1

6/4/02



### Bescheinigung

### Certificate

### Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten internationalen Patentanmeldung überein.


The attached documents are exact copies of the international patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet international spécifiée à la page suivante.

Den Haag, den  
The Hague,  
La Haye, le

05. 09. 2000

Der Präsident des Europäischen Patentamts  
Im Auftrag  
For the President of the European Patent Office  
Le Président de l'Office européen des brevets  
p. o.

  
Nicole De Bie

Patentanmeldung Nr.  
Patent application no.  
Demande de brevet n°

PCT/EP-97/00426



Anmeldung Nr.:  
Application no.:  
Demande n°:

PCT/EP 97/00426

Anmelder:  
Applicant(s):  
Demandeur(s):

1. BOEHRINGER MANNHEIM GMBH - Mannheim, Germany
2. VON EICHEL-STREIBER, Christoph - Schweppenhäusen, Germany
3. BOQUET, Patrice - Nice, France

Bezeichnung der Erfindung:

Title of the invention:

Titre de l'invention:

Method of inactivation of P21 Ras and agents therefor

Anmeldetag:

Date of filing:

Date de dépôt:

31 January 1997 (31.01.97)

In Anspruch genommene Priorität(en)

Priority(ies) claimed

Priorité(s) revendiquée(s)

Staat:

State:

Pays:

Germany

Tag:

Date:

Date:

02 February 1996

(02.02.96)

Aktenzeichen:

File no.

Numéro de dépôt:

96 101 469.3

Benennung von Vertragsstaaten : Siehe Formblatt PCT/RO/101 (beigefügt)

Designation of contracting states : See Form PCT/RO/101 (enclosed)

Désignation d'états contractants : Voir Formulaire PCT/RO/101 (ci-joint)

Bemerkungen:

Remarks:

Remarques:

Further applicant:

4. THELESTAM, Monica - Solna, Sweden

## Feld Nr. V BESTIMMUNG VON STAATEN

Die folgenden Bestimmungen nach Regel 4.9 Absatz a werden hiermit vorgenommen (bitte die entsprechenden Kästchen ankreuzen; wenigstens ein Kästchen muß angekreuzt werden):

## Regionales Patent

- ☒ AP ARIPO-Patent: KE Kenia, LS Lesotho, MW Malawi, SD Sudan, SZ Swasiland, UG Uganda und jeder weitere Staat, der Vertragsstaat des Harare-Protokolls und des PCT ist
- ☒ EA Eurasisches Patent: AM Armenien, AZ Aserbaidschan, BY Belarus, KG Kirgisistan, KZ Kasachstan, MD Republik Moldau, RU Russische Föderation, TJ Tadschikistan, TM Turkmenistan und jeder weitere Staat, der Vertragsstaat des Eurasischen Patentübereinkommens und des PCT ist
- ☒ EP Europäisches Patent: AT Österreich, BE Belgien, CH und LI Schweiz und Liechtenstein, DE Deutschland, DK Dänemark, ES Spanien, FI Finnland, FR Frankreich, GB Vereinigtes Königreich, GR Griechenland, IE Irland, IT Italien, LU Luxemburg, MC Monaco, NL Niederlande, PT Portugal, SE Schweden und jeder weitere Staat, der Vertragsstaat des Europäischen Patentübereinkommens und des PCT ist
- ☒ OA OAPI-Patent: BF Burkina Faso, BJ Benin, CF Zentralafrikanische Republik, CG Kongo, CI Côte d'Ivoire, CM Kamerun, GA Gabun, GN Guinea, ML Mali, MR Mauretanien, NE Niger, SN Senegal, TD Tschad, TG Togo und jeder weitere Staat, der Vertragsstaat der OAPI und des PCT ist (falls eine andere Schutzrechtsart oder ein sonstiges Verfahren gewünscht wird, bitte auf der gepunkteten Linie angeben) .....

Nationales Patent (falls eine andere Schutzrechtsart oder ein sonstiges Verfahren gewünscht wird, bitte auf der gepunkteten Linie angeben):

- |  |  |
|--|--|
| <input checked="" type="checkbox"/> AL Albanien .....                          | <input checked="" type="checkbox"/> LV Lettland .....  |
| <input checked="" type="checkbox"/> AM Armenien .....                          | <input checked="" type="checkbox"/> MD Republik Moldau .....                                 |
| <input checked="" type="checkbox"/> AT Österreich .....                        | <input checked="" type="checkbox"/> MG Madagaskar .....                                      |
| <input checked="" type="checkbox"/> AU Australien .....                        | <input checked="" type="checkbox"/> MK Die ehemalige jugoslawische Republik Mazedonien ..... |
| <input checked="" type="checkbox"/> AZ Aserbaidschan .....                     | <input checked="" type="checkbox"/> MN Mongolei .....  |
| <input checked="" type="checkbox"/> BB Barbados .....                          | <input checked="" type="checkbox"/> MW Malawi .....  |
| <input checked="" type="checkbox"/> BG Bulgarien .....                         | <input checked="" type="checkbox"/> MX Mexiko .....  |
| <input checked="" type="checkbox"/> BR Brasilien .....                         | <input checked="" type="checkbox"/> NO Norwegen .....  |
| <input checked="" type="checkbox"/> BY Belarus .....                           | <input checked="" type="checkbox"/> NZ Neuseeland .....                                      |
| <input checked="" type="checkbox"/> CA Kanada .....                            | <input checked="" type="checkbox"/> PL Polen .....   |
| <input checked="" type="checkbox"/> CH und LI Schweiz und Liechtenstein .....  | <input checked="" type="checkbox"/> PT Portugal .....  |
| <input checked="" type="checkbox"/> CN China .....                             | <input checked="" type="checkbox"/> RO Rumänien .....  |
| <input checked="" type="checkbox"/> CZ Tschechische Republik .....             | <input checked="" type="checkbox"/> RU Russische Föderation .....                            |
| <input checked="" type="checkbox"/> DE Deutschland .....                       | <input checked="" type="checkbox"/> SD Sudan .....   |
| <input checked="" type="checkbox"/> DK Dänemark .....                          | <input checked="" type="checkbox"/> SE Schweden .....  |
| <input checked="" type="checkbox"/> EE Estland .....                           | <input checked="" type="checkbox"/> SG Singapur .....  |
| <input checked="" type="checkbox"/> ES Spanien .....                           | <input checked="" type="checkbox"/> SI Slowenien .....                                       |
| <input checked="" type="checkbox"/> FI Finnland .....                          | <input checked="" type="checkbox"/> SK Slowakei .....  |
| <input checked="" type="checkbox"/> GB Vereinigtes Königreich .....            | <input checked="" type="checkbox"/> TJ Tadschikistan .....                                   |
| <input checked="" type="checkbox"/> GE Georgien .....                          | <input checked="" type="checkbox"/> TM Turkmenistan .....                                    |
| <input checked="" type="checkbox"/> HU Ungarn .....                            | <input checked="" type="checkbox"/> TR Türkei .....  |
| <input checked="" type="checkbox"/> IL Israel .....                            | <input checked="" type="checkbox"/> TT Trinidad und Tobago .....                             |
| <input checked="" type="checkbox"/> IS Island .....                            | <input checked="" type="checkbox"/> UA Ukraine .....   |
| <input checked="" type="checkbox"/> JP Japan .....                             | <input checked="" type="checkbox"/> UG Uganda .....  |
| <input checked="" type="checkbox"/> KE Kenia .....                             | <input checked="" type="checkbox"/> US Vereinigte Staaten von Amerika .....                  |
| <input checked="" type="checkbox"/> KG Kirgisistan .....                       | <input checked="" type="checkbox"/> UZ Usbekistan .....                                      |
| <input checked="" type="checkbox"/> KP Demokratische Volksrepublik Korea ..... | <input checked="" type="checkbox"/> VN Vietnam .....   |
| <input checked="" type="checkbox"/> KR Republik Korea .....                    |  |
| <input checked="" type="checkbox"/> KZ Kasachstan .....                        |  |
| <input checked="" type="checkbox"/> LK Sri Lanka .....                         |  |
| <input checked="" type="checkbox"/> LR Liberia .....                           |  |
| <input checked="" type="checkbox"/> LS Lesotho .....                           |  |
| <input checked="" type="checkbox"/> LT Litauen .....                           |  |
| <input checked="" type="checkbox"/> LU Luxemburg .....                         |  |

Kästchen für die Bestimmung von Staaten (für die Zwecke eines nationalen Patents), die dem PCT nach der Veröffentlichung dieses Formblatts beigetreten sind:

- ☒ CU Cuba .....
- ☒ LC St. Lucia .....
- ☒ BA Bosnien-Herzegowina .....

Zusätzlich zu den oben genannten Bestimmungen nimmt der Anmelder nach Regel 4.9 Absatz b auch alle anderen nach dem PCT zulässigen Bestimmungen vor mit Ausnahme der Bestimmung von .....

Der Anmelder erklärt, daß diese zusätzlichen Bestimmungen unter dem Vorbehalt einer Bestätigung stehen und jede zusätzliche Bestimmung, die vor Ablauf von 15 Monaten ab dem Prioritätsdatum nicht bestätigt wurde, nach Ablauf dieser Frist als vom Anmelder zurückgenommen gilt. (Die Bestätigung einer Bestimmung erfolgt durch die Einreichung einer Mitteilung, in der diese Bestimmung angegeben wird, und die Zahlung der Bestimmungs- und der Bestätigungsgebühr. Die Bestätigung muß beim Anmeldeamt innerhalb der Frist von 15 Monaten eingehen.)

BOEHRINGER MANNHEIM GMBH

4355/0A/WO

**Method of inactivation of P21 Ras and agents therefor**

The invention relates to methods of inactivation of p21 Ras, especially in its active oncogenic mutation, and agents therefor.

It is known that many diseases result from aberrations in signalling pathways. It is apparent that proto-oncogenes and oncogenes code for proteins which are involved in cell signalling and participate in the regulation of cell proliferation, cell division and cell death. Thus, growth factors, and their receptors, cellular tyrosine kinases, Ras proteins, adaptor molecules, cyclins and transcription factors and their co-factor proteins play a pivotal role in cell proliferation. Activating mutations of such molecules disrupt the normal patterns of signalling and lead, in some cases, to enhanced cell growth. Such an initial oncogenic mutation is, for example, the mutation glycine 12 to valine in the Ras proto-oncogene.

Further signal transduction molecules modified by our enzymic activity are Rac of the Rho subfamily, Rap and Ral of the Ras subfamily of small GTP-binding proteins.

Oncogenic mutation in Ras occurs in 40% of all cancer, and over 85% of certain cancers, such as pancreatic cancer and colon cancer. The oncogenic form of Ras continues to be involved even at the advanced stages of colon cancer, although in many instances, it is the first oncogenic mutation which occurs in the colon tissue (Shirasawa et al., Science 260 (1993) 85-88). The Ras proto-oncoproteins are activated by upstream mitogenic signals such as receptor tyrosine kinase and mitogenic peptides which act via the serpentine receptor GTP-binding protein signal-transduction system. Therefore, Ras is a transducer of upstream mitogenic signals, and an oncoprotein, when mutated. Thus, inhibition of Ras function is a prime target for cancer therapy.

Inhibition of Ras function can be obtained by inhibition of Ras farnesylation. The enzyme farnesyl protein transferase catalyzes the farnesylation of Ras by farnesyl pyrophosphate. Such inhibitors are described, for example, by Kohl, N.E., et al., Science 260 (1993) 1934-1937. It is further discussed to inhibit Ras activation by gribstatins or sostatins (Razakis-Adocke, M., et al., Nature 363 (1993) 83-85; Segal, M., et al., Proc. Natl. Acad. Sci. USA 90 (1993) 5564-5568). It is further proposed to inhibit Ras/Raf-1 interaction (Levitzky, A., Euro. J.

Biochem. 226 (1994) 1-13). The efficiency of the inhibition of the Ras pathway by the known substances is not yet satisfactory however.

The Ras inhibitors which are known are non-peptidic substances. For cell-specific targeting, however, preferably, fusion proteins, in particular, immunotoxins, are used, which can be prepared chemically or by genetic engineering techniques. However, no toxin is known which specifically inhibits active Ras oncoproteins in mammalian, especially human, cells.

Several different species of the genus *Clostridium* produce large molecular weight (250-300 kDa) cytotoxins which cause effects on the actin cytoskeleton, including disruption of actin stress fibers and rounding up of cell bodies. This sub-group of clostridial cytotoxins includes toxins A and B from *Clostridium difficile*, lethal toxin (LT) and hemorrhagic toxin (HT) from *Clostridium sordellii*, and *Clostridium novyi*  $\alpha$ -toxin (Bette, P., et al., Toxicon 29 (1991) 877-887). Enterotoxin A and cytotoxin B have been characterized by Sullivan, N.M., et al., Infect. Immun. 35 (1982) 1032-1040, von Eichel-Streiber, C., et al., Microbiol. Pathogenesis 2 (1987) 307-318. Toxin A and toxin B are glucosyltransferases which modify threonine 37 of the GTPase Rho. By attracting of glucose at this position of Rho, this GTPase is blocked in its function. Recently, toxin B and toxin A from *C. difficile*, the causative agent of antibiotic-associated diarrhea (Lyerly, D.M., et al., Clin. Microbiol. Rev. 1 (1988) 1-18), were shown to covalently modify the mammalian protein Rho by UDP-Glc dependent glucosylation of threonine 37 (Just, I., et al., Nature 375 (1995) 500-503; Just, I., et al., J. Biol. Chem. 270 (1995) 13932-13936). Rho is a small Ras related GTP-binding protein involved in the control of actin polymerization (Hall, A., Ann. Rev. Cell. Biol. 10 (1994) 31-34). Glucosylation of threonine 37 of Rho by *C. difficile* toxins A or B apparently inactivates this protein and results in a loss of actin stress-fiber assembly.

*C. sordellii* produces two toxins; LT and HT, two major virulence factors inducing gas gangrene and hemorrhagic diarrhea in humans and animals (Arseculeratne, S.N., et al., J. Med. Microbiol. 2 (1969) 37-53). These *C. sordellii* toxins have some similarities with the toxins A and B of *C. difficile* in terms of amino-acid sequences and immunological epitopes (Martinez, R.D., and Wilkins, T.D., J. Med. Microbiol. 36 (1992) 30-32). Despite these similarities, it seems that LT and toxins A or B affect different intracellular target proteins. LT causes morphological and cytoskeletal effects different from those elicited by the *C. difficile* toxins. The effects consist in the rounding of cell bodies with the reorganization of F-actin structures into numerous cell surface filopodia and a loss of actin stress-fibers (Popoff, M.R., Infect. Immun. 55 (1987) 35-43; Giry, M., et al., Infect. Immun. 63 (1995) 4063-4071). In addition,

it was shown that overexpression of Rho A, B or C cDNAs in HeLa cells protects these cells from the effects of toxin A and B but not from that of LT (Giry, M., et al., Infect. Immun. 63 (1995) 4063-4071). These observations clearly pointed out that Rho small GTP-binding proteins were the main substrate for the *C. difficile* toxins.

Toxins A and B from *C. difficile* have been shown to covalently modify and thereby inactivate the small GTP-binding protein Rho resulting in the disruption of F-actin structures (Just, I., et al., J. Biol. Chem. 269 (1994) 10706-10712; Just, I., et al., J. Clin. Invest. 95 (1995) 1026-1031). "In vitro" and "in vivo" evidence indicates that toxins A and B modify Rho A by UDP-Glc dependent glucosylation of threonine 37 (Just, I., et al., Nature 375 (1995) 500-503; Just, I., et al., J. Biol. Chem. 270 (1995) 13932-13936). In addition to Rho A toxins A and B of *C. difficile* also "in vitro" modify Rac1 and Cdc42 (Just, I., et al., Nature 375 (1995) 500-503; Just, I., et al., J. Biol. Chem. 270 (1995) 13932-13936), two other proteins of the Rho sub-family involved in the control of membrane ruffling and filopodia formation respectively (Ridley, A.J., et al., Cell 70 (1992) 401-410; Nobes, C.D., and Hall, A., Cell 81 (1995) 53-62). Also, it has recently been reported that the  $\alpha$  toxin from *C. novyi* is a glucosyl-transferase which acts on the cytoskeleton through modification of Rho. However, in this case, UDP-Glc was not the cofactor required for modification.

M.R. Popoff, in Infect. Immun. 55 (1987) 35-43, describes a purification protocol for *C. sordellii* lethal toxin (LT) as well as phenomenology of LT action. Popoff does not state anything about the molecular targets or the enzymatic action of LT.

G.A. Green et al., in Gene 161 (1995) 57-61, describe the cloning and sequencing of the LT encoding gene of strain 6018. The authors do not present any clue towards the mode of action of LT.

C. v. Eichel-Streiber, in Mol. Microbiol. 17 (1995) 313-321, provides data which indicate that some *C. difficile* toxins behave like *C. sordellii* LT. ToxB-1470 induces morphological effects identical to those of LT, but both clearly different from those of ToxB. The sequence of tcdB-1470 is presented and a comparison of tcdB of *C. difficile* strain VPI10463 is shown that narrows down the catalytic domain of the toxins to approximately the 900 amino acids from the amino-terminus on.

WO 94/22476 describes the use of Saponin as an adjuvant in preparing a multivalent vaccine against bacteria and toxins of the genus Clostridia. *C. sordellii* is one of the strains the

described immunization is addressed to. Strain and/or toxin are used as antigens for inducing protection in animals after different routes of inoculation.

### **Summary of the invention**

The invention provides a method for the inhibition of p21 Ras by a polypeptide with glucosylation activity of lethal toxin (LT) from *Clostridium sordellii*. It was, surprisingly, found that LT inactivates Ras by glucosylation of Ras subfamily proteins, preferably by glucosylation of Ras threonine 35. This was completely unexpected because the toxins A and B, which are, in regard to their sequence, largely homologous to LT, inactivate small G-proteins of only the Rho subfamily.

An object of the invention, therefore, is a method of treating a patient with a disorder, characterized by an activating mutation in the Ras proto-oncogene, comprising contacting cells, preferably, specifically tumor cells, of said patient with a protein having the toxic activity of *Clostridium sordellii* toxin LT under conditions favoring inactivating of Ras by glucosylation of threonine 35 in said cell. Such a disorder is, preferably, cancer, more preferably, pancreas or colon cancer.

A further object of the invention is an immunotoxin with the glucosylating activity of toxin LT, whereby Ras is inactivated by glucosylation of Ras' threonine 35.

A further object of the invention is a method wherein said immunotoxin contains a first part, a second part, and a third part, connected by covalent bonds:

- (i) the first part including a target cell specific binding domain, which domain is able to cause the immunotoxin to bind to said patient's cell;
- (ii) the second part including a translocation domain of a protein, which domain is capable of translocating the third part across the cytoplasmic membrane of the cell, and
- (iii) the third part including a polypeptide with the toxic activity of the catalytic domain of toxin LT from *Clostridium sordellii* LT.

Such an immunotoxin preferably contains, as the target cell, a specific binding domain, the antibody or active fragment thereof.

A further object of the invention is a composition useful in treating a pathological condition, characterized by an activating mutation in the Ras proto-oncogene, comprising an immunotoxin which contains a first part, a second part, and a third part, connected by covalent bonds:

- (i) the first part including a target cell specific binding domain, which domain is able to cause the immunotoxin to bind to said patient's cell;
- (ii) the second part including a translocation domain of a protein, which domain is capable of translocating the third part across the cytoplasmic membrane of the cell, and
- (iii) the third part including a polypeptide with the toxic activity of the catalytic domain of toxin LT from *Clostridium sordellii* LT,

and a pharmaceutically acceptable carrier.

A further object of the invention is the afore-mentioned immunotoxin, wherein the first part preferably is an antibody or an active fragment thereof.

A further object of the invention is an immunotoxin with the glucosylating activity of toxin LT on Ras.

A further object of the invention is a method of manufacturing a therapeutic agent, characterized by combining a therapeutically useful amount of an immunotoxin according to the invention with a therapeutically acceptable adjuvant or carrier.

#### **Detailed description of the invention**

It was found that LT, like toxins A and B of *C. difficile*, is also a glucosyltransferase using UDP-Glc to modify small GTP-binding proteins. Surprisingly, LT "in vitro" glucosylates Ras, Rap2, Ral and Rac1. The Ral modification is not seen if a GST-fusion protein is used as target molecule (compare Figures 3A and 3B). LT had no effect on Rho, nor on Cdc 42, two of the main substrates for *C. difficile* A and B toxins.

The effects induced by LT on the HeLa cell actin cytoskeleton are obviously different from those elicited by toxins A and B of *C. difficile*. The LT effects consist in the disruption of actin-stress-fibers and the formation of filopodia containing F-actin and fimbrin/plastin (Giry, M., et al., Infect. Immun. 63 (1995) 4063-4071). Glucosyltransferase activity of both *C*



*difficile* and *C. novyi* toxins is directed towards GTP-binding proteins of the Rho-subfamily. *C. sordellii* LT is the first toxin which mainly acts on the Ras-subfamily of GTPases. The specific effect of LT on the HeLa cell actin cytoskeleton is fundamentally different to what is observed with Tox A or B of *C. difficile* (Giry, M., et al., Infect. Immun. 63 (1995) 4063-4071). Since both Tox B (or A) and LT are able to glucosylate Rac (Just, I., et al., Nature 375 (1995) 500-503; Just, I., et al., J. Biol. Chem. 270 (1995) 13932-13936), the specific activity of LT on the cytoskeleton cannot be attributed to Rac modification alone. It seems that the combination of the modified GTPases causes LT to induce its cytopathogenic effect. Thus, Rap and Ral modification by LT could be a key event for LT actin cytoskeleton activity.

LT inactivates Ras by glucosylation of threonine 35 which corresponds to threonine 37 of Rho (Madaule, P., and Axel, R., Cell 41 (1985) 31-40), the residue modified by toxins A and B (Just, I., et al., Nature 375 (1995) 500-503; Just, I., et al., J. Biol. Chem. 270 (1995) 13932-13936). LT acts in the cytosol and "in vivo" glucosylates small Mr 21 kDa molecules resulting in the inactivation of Ras, since serum-starved Swiss 3T3 cells intoxicated with LT have no Ras-dependent induced MAP-kinase phosphorylation (see Fig. 5).

It seems reasonable that amino acid sequences apart from the threonine 35 acceptor site of glucosylation enable LT to specifically recognize the various small G-proteins.

LT-glucosylation of Ras on threonine 35 induced a small but significant decrease in the  $K_{off}$  of GDP, most likely due to a higher affinity of the glucosylated Ras for magnesium. Such a difference in magnesium affinity has not been observed for the threonine 35 alanine ([T35A]) mutant of Ras (John, J., et al., J. Biol. Chem. 268 (1993) 923-929). Apart from this small difference, the T35 glucosylated form of Ras in the GTP-bound form has properties very similar to those of the [T35A] mutant: a 4 fold increase in the GTP  $K_{off}$  and a 4 to 5 times slower rate of GTP hydrolysis (John, J., et al., J. Biol. Chem. 268 (1993) 923-929). It therefore seems that the T35 glucosylation of Ras, as the [T35A] mutant of Ras, has a much decreased affinity for the Raf Ras-binding domain (RBD) (Herrmann, C., et al., J. Biol. Chem. 270 (1995) 2901-2905). The [T35A] mutant of Ras has a 200 fold reduced affinity for Raf-RBD (Herrmann, C., et al., J. Biol. Chem. 270 (1995) 2901-2905) and represents the mutation that has the most drastic effect on Ras-RBD interaction (Herrmann, C., et al., J. Biol. Chem. 270 (1995) 2901-2905). Threonine 35 contacts both magnesium and  $\gamma$ -phosphate in the GTP-bound form, and a water molecule which also makes a hydrogen bond with aspartic acid 38 in the Rap/Raf-RBD complex (Nassar, N., et al., Nature 375 (1995) 554-560). Threonine 35 is conserved in all of the small G-proteins and is an essential residue of the

switch I region (Pai, E.F., et al., EMBO J. 9 (1990) 2351-2359). Thus the modification of threonine 35 either by mutation [T35A] or by glucosylation would result in the inability of Ras to interact with its effector (Pai, E.F., et al., EMBO J. 9 (1990) 2351-2359). Even the conservative threonine 35 serine mutation greatly decreases (about 20 fold) the transforming potential of an oncogenic Ras, pointing to the importance of this residue in switching to the active conformation and/or interacting with the Raf effector (White, M.A., et al., Cell 80 (1995) 533-541).

Taking into account that LT is the first toxin which inactivates the Ras small GTP-binding protein, it is a powerful laboratory reagent to explore cellular signalling pathways stimulated by this molecule and a useful therapeutic agent for inhibiting Ras activity in vivo. Toxin LT is organized like many other bacterial toxins, especially like *C. difficile* toxins A and B (von Eichel-Streiber, C., et al., Mol. Microbiol. 17 (1995) 313-321; von Eichel-Streiber, C., et al., Trends in Microbiology 4 (October 1996) 375-382) or *P. aeruginosa* exotoxin A., and all clostridial neurotoxins (Choe, S., et al., Nature 357 (1992) 216-222; Allured, V.S., et al., Proc. Natl. Acad. Sci. USA 83 (1986) 1320-1324; Prior, T.I., et al., Biochemistry 31 (1992) 3555-3559; Montecucco, C., and Schiava, G., Trends Biochem. Sci. 18 (1993) 324-326). Especially toxin LT is organized as a single-chained toxin consisting of three domains: The N-terminal domain constitutes the catalytic domain, followed by the intermediary translocation domain, and the final C-terminal region contributing to cellular binding. The DNA and protein sequence of toxin LT are described in Green, G.A., et al., Gene 161 (1995) 57-61, and EMBL DataBank Access No. X82638. The catalytic domain of the toxin consists of approximately the first 1020 amino acids of the sequence or parts thereof which have the glucosyltransferase activity of LT.

An immunotoxin according to the invention is a multidomain protein containing a first part, a second part and a third part usually connected by covalent bonds:

1. the first part including a target cell specific binding domain of a cell binding ligand, which domain is able to cause the immunotoxin to bind to a target mammalian, especially human, cell;
2. the second part including a translocation domain of a protein, which domain is capable of translocating the third part across the cytoplasmic membrane of the cell, and
3. the third part including a polypeptide with the activity of the toxin domain (the catalytic domain) of toxin LT.

The hybrid molecule is produced by expression of a recombinant DNA molecule encoding the multidomain protein molecule or by chemical linkage between the domains (see e.g. Monoclonal Antibodies in Clinical Medicine, ed. McMichael, A.J., and Fabre, J.W., Academic Press, London (1982) 168-192).

The *first part* is a moiety which binds specifically to the target cells. Therefore, as the first part there is used a binding partner for a surface receptor or marker which is highly expressed on tumor cells and has a high degree of selectivity for tumor cells. The receptor for the binding partner is a surface molecule on the target cells which is expressed in considerably higher amounts and to a larger extent on the target cells than on normal cells. Examples for such suitable binding partners are antibodies, cytokines, melanoma stimulating hormone (MSH), other hormones or growth factors.

The target cell-specific binding domain recognizing a cell surface structure, such as a receptor protein or a surface antigen on the target cell, is e.g. derivable from a ligand of a cell specific receptor, such as a Fc receptor, transferrin receptor, EGF receptor, asialoglycoprotein receptor, cytokine receptor, such as a lymphokine receptor, a T cell specific receptor, e.g. CD 45, CD4 or CD8, the CD 3 receptor complex, TNF receptor, CD 25, erbB-2, an adhesion molecule, such as NCAM or ICAM, and mucine. Suitable ligands include antibodies specific for said receptor or antigen. Further molecules suitable as ligand domain in the multidomain protein of the invention include factors and growth factors, e.g. tumor necrosis factor, e.g. TNF- $\alpha$ , human growth factor, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), transforming growth factor (TGF), such as TGF $\alpha$  or TGF $\beta$ , nerve growth factor, insulin-like growth factor, a peptide hormone, e.g. glucagon, growth hormone, prolactin, or thyroid hormone, a cytokine, such as interleukin, e.g. IL-2 or IL-4, interferon, e.g. IFN- $\gamma$ , or fragments or mutants of such proteins with the provision that such fragments and mutants fulfill the above requirements for a ligand domain. For example, suitable antibody fragments include Fab fragments, Fv constructs, e.g. single chain Fv constructs (scFv) or an Fv construct involving a disulfide bridge, and the heavy chain variable domain. The ligand domain may be of natural or synthetic origin and will vary with the particular type of target cell.

Further B lymphocyte specific MAbs which are useful binding partners are the pan-B MAbs, such as anti-CD20, CD21, CD22 or anti-CD37. These MAbs, labeled with high doses of  $^{131}\text{I}$ , have been used with some success for B cell lymphoma therapy (Press, O.W., et al., J. Clin. Onc. 7 (1989) 1027-1038; Goldenberg, et al., J. Clin. Oncology 9 (1991) 548 - 568;

Kaminski, et al., New England Journal of Medicine 329 (1993) 459 - 465; Press, et al., New England Journal of Medicine 329 (1993) 1219 - 1224).

For the treatment of T cell lymphomas, MAbs specific for either the idiotype or the  $\alpha$  or  $\beta$  chain of the T cell receptor (TCR) are useful in the conjugates according to the invention. Some of these anti- $\alpha$  or  $\beta$  chain MAbs from TCR were first described as anti-T cell idiotypes (Reinherz, E.L., et al., Immunol Rev. 74 (1983) 83-112; Carrel, S., et al., Eur.J Immunol., 16 (1986) 649-652) but were subsequently found to be shared by 1 to 10% of normal T lymphocytes.

Glioblastoma cells also show various degrees of expression of class II MHC which can be enhanced by interferon- $\gamma$ . A certain percentage (40 to 60%) of glioma express a high density of the EGF receptor, which could be a good target for the conjugates (Kalofonos, H.P., et al., J. Nucl. Med. 30 (1989) 1636-1645; Humphrey, P.A., et al., Proc. Natl. Acad. Sci. U S A 87 (1990) 4207-4211), especially if the conjugates are injected locally in cystic tumors or after surgical removal of the major part of the tumor. In the case of an intracranial injection of the conjugates it is preferred to inject also locally autologous peripheral blood lymphocytes containing effector T cells capable of recognizing the tumor cells with immunogenic peptides on their surface associated with MHC.

Carcinoma cells rarely express class II MHC. Thus, it is preferred to use the class I processing pathway in order to apply a therapy to these tumors. Several MAbs with different degrees of selectivity for carcinoma cells have been described. Some of them, such as those reacting with the Erb-B2 receptor (Harwerth, I.-M., et al., J. Biol. Chem. 21 (1992) 15160-15167; Batra, J.K., et al., Proc. Natl. Acad. Sci. USA 89 (1992) 5867-5871; Kasprzyk, P.G., et al., Cancer Res. 52 (1992) 2771-2776; Wels, W., et al., Cancer Res. 52 (1992) 6310-6317) and/or the EGF receptor (Atlas, I., et al., Cancer Res. 52 (1992) 3335-3339) or MAb A33 from the group of Old (Welt, S., et al., J. Clin. Oncol. 8 (1990) 1894-1906), are readily internalized by carcinoma cells and could be used in the method according to the invention.

The *second part* is a "translocation domain". "Translocation" means the facilitation of movement of the catalytic domain (in the case of LT: glucosyltransferase) from the exterior surface of a cellular membrane (or what constituted the exterior surface prior to formation of an endocytic vesicle) through the membrane and into the cytosol at the interior of the cell. This domain is therefore a segment of a protein which, when the protein is bound to the exterior surface of a cellular membrane, is capable of translocating some portion of that

protein through the membrane. As translocation domain it is preferred to use the translocation domain of a naturally occurring toxin (e.g. diphtheria toxin or *Pseudomonas* exotoxin or toxin LT). The translocation domain of diphtheria toxin consists, for example, essentially of amino acids Ser<sup>194</sup> to Ser<sup>535</sup>.

A further object of the invention is a vector, especially a retroviral or non-viral vector, which interacts with tumor cells and carries the catalytic principle of toxin LT. Said vector contains a nucleotide acid fragment which codes for the first 1020 amino acids of toxin LT or parts thereof which have the toxic activity of the catalytic domain of LT.

The *third part* of the multidomain protein according to the invention is the catalytic domain. Toxin LT can be isolated according to Popoff, M.R., Infect. Immun. 55 (1987) 35-43, or modified according to von Eichel-Streiber, C., et al., Microbiol. Pathogenesis 2 (1987) 307-318. Its sequence is described by Green, G.A., et al., Gene 161 (1995) 57-61. The toxin domain consists of approximately the first 1000 amino acids of this sequence. In the multidomain protein according to the invention, the length of the toxin domain can vary as long as the toxic activity remains essentially unchanged.

In a preferred embodiment, the second and the third part of the multidomain protein result from toxin LT. Therefore, the protein contains the translocation domain and the catalytic domain of LT. Thus, this combined second and third parts comprise approximately the first amino acids 1-1020 and 1021-1700 of the LT sequence (from the N-terminus on).

Immunotoxins according to the invention can be produced by either of two principally different methods:

In one method, an antibody or a fragment thereof (normally generated proteolytically, e.g. Fab-fragment) is chemically coupled in vitro to a toxin or toxin fragment. For practical reasons, the antibody part in this type of immunotoxin is either a complete antibody (consisting of two light and two heavy chains) or, more preferably, a Fab-fragment (consisting of one light chain and the VH- and CH1-regions of the heavy chain). The chemical coupling of the toxin part to the antibody part will not normally lead to a completely defined, homogeneous immunotoxin molecule, as surface residues in different positions may participate. In addition, the ratio of antibody to toxin will vary to a certain degree.

In the other method, the immunotoxin is generated by recombinant DNA techniques, which leads in any case to a defined, homogeneous molecule. The size of the antibody part should be as small as possible to obtain a small immunotoxin with good tissue penetration. In this method, the smallest practically available antibody fragment is not the Fab-fragment, but the functional variable domain of an antibody, consisting of the VH-region of the heavy chain and the VL-region of the light chain only. VH- and VL-region (polypeptide chains each of about 100 amino acids) have to form a functional assembly, the variable domain, which confers antigen binding. In the absence of any of the remaining parts of an antibody, VH- and VL-region form very labile complexes only. Therefore, their complex is preferably stabilized by covalent bonds.

One possibility is to fuse on the DNA level VH-region, VL-region (or vice versa) and the toxin part. Upon expression, a single polypeptide chain is formed, wherein VH- and VL-region, being connected by a peptide linker, fold into a stable variable domain, while the toxin is fused e.g. to VL via a second peptide linker (see Brinkmann et al. 1992, PNAS 89, 3075 - 3079). The length of both peptide linkers is variable and may in some instances even be reduced to a single peptide bond. A molecule of this type has been termed a "single chain immunotoxin", analogous to the term "single chain antibody" or scFV, which is used for a single polypeptide chain containing both VH and VL connected by a peptide linker or bond.

Another possibility to stabilize the VH- and VL-assembly is described in Brinkmann et al. 1993 (PNAS 90, 7538 - 7542). In this technique, amino acids on VH and VL were defined by computer aided modelling, which are closely adjacent in the VH-VL-complex. The naturally occurring amino acids in these positions were then on the DNA level replaced by a cysteine each. To obtain a functional immunotoxin in this case, two separate polypeptide chains are expressed (in separate *E. coli* cells), one being the VH-region only, the other the VL-region fused by a peptide linker to the toxin part. These two polypeptide chains are mixed under appropriate conditions and thus assemble into a functional immunotoxin, where VH and VL in the variable antibody domain are connected by a disulfide bond between the two cysteines introduced by genetic engineering. The antibody part of this type of immunotoxin has been designated dsFV and the whole molecule consequently as "dsFV-immunotoxin".

Of course, there exist additional possibilities to produce immunotoxins by recombinant DNA techniques, for instance by using the larger Fab-fragment (VH-CH1 non-covalently assembled to VL-CL, while one of them is fused by a peptide linker to the toxin). However, the possibilities described by Brinkmann et al. 1992 and Brinkmann et al. 1993 are to be preferred.

An immunotoxin is produced preferably as a single polypeptide chain in *E. coli*. The polypeptide is obtained in an inactive form and has to be activated by in vitro renaturation.

In another method, an immunotoxin is produced as two polypeptide chains in two separate *E. coli* strains. Both polypeptides are obtained in an inactive form. They are mixed in equimolar amounts and activated by in vitro renaturation. During this process, both polypeptides assemble to the active heterodimeric immunotoxin.

Such immunotoxins and methods of producing same are described, for example, in EP-B 0 194 276, WO 88/01649, US Patent No. 4,947,778, WO 88/09344, US Patent No. 5,132,405 and US Patent No. 5,091,513

A further object of the invention is a retroviral or non-viral vector which contains a nucleic acid fragment which codes at least for a translocation domain and the catalytic domain of LT. Such a vector can be used as a gene therapeutic agent for transfection of tumor cells of a patient. There is preferably used a retroviral or non-viral vector utilizable for transformation of tumor cells, which mediates expression of the aminoterminal 1020 amino acids, or a fragment thereof with preserved glucosyltransferase activity. This vector can be used in an in vivo or ex vivo gene therapy.

Within the multidomain protein of the invention the translocation domain functions to enhance the transfer of the catalytic domain through the cellular or endosomal membrane into the cytosome. WO 94/04696 describes a nucleic acid transfer system wherein, as a translocation domain and a receptor binding domain, the cognate domains of *P. exotoxin A* are used. However, the transfection efficiency and specificity of such transfer systems are very low. The invention, therefore, provides an improved nucleic acid transfer system exhibiting a high transfection efficiency and specificity. Suitable translocation domains are derivable from toxins, particularly bacterial toxins, such as *C. difficile* toxin A or B, *C. sordellii* toxin LT, exotoxin A, Colicin A, d-endotoxin, diphtheria toxin, *Bacillus anthrax* toxin, Cholera toxin, Pertussis toxin, *E. coli* toxins, Shigatoxin or a Shiga-like toxin. The translocation domain does not include that part of the parent toxin molecule which confers the toxic effect of the molecule, except when the parent toxin is toxin LT. Advantageously, the translocation domain of the recombinant protein of the invention is derivable or essentially derivable from that very part of the parent toxin which mediates internalization of the toxin into the cell, e.g. amino acids 193 or 196 to 378 or 384 of diphtheria toxin.

The following examples, references, sequence listing and drawing are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

### Sequence Listing

SEQ ID NO:1	Primer BCS1C (bases 465-495 of the total sequence (EMBL DataBank Accession No. X82638).
SEQ ID NO:2	Primer BCD2N (complementary to bases 3528-3556 of the total sequence)
SEQ ID NO:3	Primer BCD2C (bases 3528-3556 of the total sequence)
SEQ ID NO:4	Primer BCS3N (complementary to bases 5552-5579 of the total sequence)

### Figure Legends

**Fig. 1: *LT induced Glucosylation of Mr 21 kDa proteins in HeLa cell lysates:*** HeLa cell lysates were incubated with UDP-[<sup>14</sup>C] Glc in the absence (lane A) or presence (B-D) of LT. Specificity of UDP-Glc labelling by LT was tested by incubating HeLa lysates with a 10 fold excess of unlabeled UDP-Glc (C) or UDP-glucuronic acid (D) together with UDP-[<sup>14</sup>C] Glc. M<sub>r</sub> are in kiloDalton.

**Fig. 2: *"In vivo" glucosylation of cellular Mr 21 kDa proteins in Rat fibroblasts by LT:*** Rat-1-EJ-Rap2.31.A8 fibroblasts were incubated with the indicated concentrations of LT for 120 min detached from the culture dishes, lysed and glucosylated by LT with UDP-[<sup>14</sup>C] Glc as described in the Methods section. Lane A; shows labelling of Mr 21 kDa proteins in cells not incubated with LT "in vivo" prior to the radioactive "in vitro" LT glucosylation of the cell lysate. B, C, D and E; show labelling of Mr 21 kDa proteins in cells incubated first "in vivo"



with respectively 5, 0.5, 0.05, and 0.005 mg/ml of LT prior to the radioactive "in vitro" LT glucosylation of the cell lysates

**Fig. 3A:** *Glucosylation of recombinant Ras-related GTPases by LT:* H-Ras, Rap2, Rac1, Cdc42, RhoA, Rab6, Ral-GST and Rac-GST (ca 1mg/assay) were incubated with LT and UDP-[<sup>14</sup>C] Glc. Panel A; Phosphorimage. B; Coomassie staining of the gel. M<sub>r</sub> are in kiloDalton.

**Fig. 3B:** *Autoradiogram of the glucosylation of the Ral-GTPase by the following clostridial cytotoxins:* lanes 1 and 2, *C. difficile* strain-10463 toxins: 1: TcdA, 2: TcdB; lanes 3 and 4, *C. difficile* strain-1470 toxins: 3: TcdA; 4: TcdB; lane 5: glucosylation of Ral by LT prepared from *C. sordellii* IP-82; lane 6: Ral-modification by TcdB of *C. difficile* strain-8864.

**Fig. 4:** *Localization of the LT catalyzed [<sup>14</sup>C] glucosylation in H-Ras by microsequencing:* Panel A; Separation by HPLC of the peptides generated by trypsin and radioactivity of each fraction (on 15 ml aliquot). B and C; Purification by HPLC of fractions 39 and 40. Radioactivity associated with each peptide was counted on 50 ml aliquots. D; Radioactivity associated with each Edman degradation cycle (each Edman cycle of peptide E and peptide D were combined and counted).

**Fig. 5:** *EGF-induced mobility shift of MAP-kinases in cells pretreated with LT:* Serum starved Swiss 3T3 cells were treated with EGF and LT as shown in the figure. Cells were lysed and about 30 mg of total protein per experiment were electrophoresed and blotted and stained with the monoclonal antibody MK12. (ERK1: 44 kDa; ERK2: 42 kDa).

**Fig. 6:** *Intracellular modulation of LT-action:* A and B; phase contrast micrographs of Don-wt cells: A, typical cytopathogenic effect observed after treatment with LT (1.25 µg/ml; 3 h) in the presence of pre-immune serum (1/200 dilution). B, neutralisation of the cytopathogenic effect by adding rabbit anti-LT antibodies (dilution 1/200) to the medium containing LT (1.25 µg/ml; 3 h). C-H; microinjection experiments of Don-wt (C, D, G, H) or Don-Q (E, F) cells. C, E, G, fluorescence micrographs of D, F, H, (phase contrast micrographs) respectively. Big arrowheads point to cells microinjected, small arrowheads to cells solely treated with substances added to the medium. Fluorescein-staining was due to FITC-dextran added to the injected medium. C and D; typical rounding of Don-wt cells microinjected with LT (concentration in the micropipette 200 µg/ml) in a medium containing LT antibodies (dilution 1/200) to protect against any LT molecules possibly leaking out from injected cells. E and F;

typical rounding of UDP-Glc deficient Don-Q cells exposed to LT (1.25 µg/ml; 3 h) in the medium, and then microinjected with UDP-Glc (concentration in the micropipette 100 mM). **G** and **H**; protection from rounding of Don-wt cells microinjected with neutralising anti-LT antibodies (serum diluted 1/10) and exposed to LT (1.25 µg/ml; 3 h) in the medium. The toxin is accessible to neutralising anti-LT antibodies once it reaches the cytosol.

**Fig. 7: Effect of LT catalysed glucosylation on nucleotide dissociation, GTPase activity and intrinsic fluorescence of [Y64W]Ras:** Panel **A**; GDP and GTP dissociation at low magnesium. Glucosylated or unmodified [Y64W]Ras-GDP (0.5 µM) was activated, in the presence of 0.8 µM free magnesium (1 mM MgCl<sub>2</sub> and 2 mM EDTA), by the addition of 10 µM GTP (first arrow) deactivation was achieved by the addition of 500 µM GDP while its intrinsic fluorescence at 340 nm was continuously monitored. GDP dissociation rate constant: glucosylated : 0.0125 s<sup>-1</sup> ; control : 0.017 s<sup>-1</sup>. GTP dissociation rate constant: glucosylated : 0.0125 s<sup>-1</sup> ; control : 0.0033 s<sup>-1</sup>. **B**; GTP hydrolysis at 1 mM magnesium. Glucosylated or unmodified [Y64W]Ras-GDP (0.5 µM) were incubated with 10 µM GTP in the presence of 1 mM magnesium. GDP/GTP exchange was initiated by the addition of 2 mM EDTA. After 6 minutes, GTP hydrolysis was initiated by the addition of 2 mM MgCl<sub>2</sub> (1 mM free magnesium). Note the change in time scale after magnesium addition. **C**; Glucosylation of [Y64W]Ras-GDP induces a small increase in the intrinsic fluorescence of the protein. The fluorescence of [Y64W]Ras-GDP was continuously monitored while 0.8 µg/ml and 100 µM UDP-Glc were sequentially added to the fluorescence cuvette. In **A** and **C**, the sample was excited at 300 nm to minimize light absorption due to the large amount of nucleotides used in these experiments. In panel **B**, the excitation was set at 292 nm.

## Examples

### **1. Materials**

*C. sordellii* LT toxin was obtained from culture supernatants of the pathogenic *C. sordellii* IP82 strain and purified to homogeneity as previously described (Popoff, M.R., Infect. Immun. 55 (1987) 35-43). Recombinant H-Ras, RhoA, Rac1, Rap2, Ral, Rab6 and Cdc42 proteins were made either in baculovirus (Rac1, Rab6 and Arf1) or in *E. coli* through either GST-fusions (H-Ras, Rap1, Ral, RhoA and Rac1) or a Histidine-tagged fusion (His-Cdc42). The monoclonal antibody MK12 (Zymed, Cal.) was used for immunoblotting MAP kinases. The recombinant tyrosine 64 tryptophan ([Y64W]) Ras mutant used for tryptophan fluorescence

experiments was produced in *E. coli* and purified as previously described (Antonny, B., et al., Biochemistry 30 (1991) 8287-8295).

## **2. Methods**

### **2.1 Glucosylation reactions**

Incorporation of LT-catalyzed [ $^{14}\text{C}$ ] Glc in the GTPases or cell lysates, was performed as described by Just et al. (Nature 375 (1995) 500-503) in the case of *C. difficile* toxin B. Briefly, 10  $\mu\text{l}$  of UDP-[ $^{14}\text{C}$ ] Glc in ethanol (0,2  $\mu\text{Ci}$ ) (300 mCi/mmol Dupont-NEN, Les Ulis, France) was dried down under vacuum. Recombinant proteins (2  $\mu\text{g}$ ) dissolved in 15  $\mu\text{l}$  of 50 mM triethanolamine-HCl buffer pH 7.5 containing 2 mM  $\text{MgCl}_2$ , 150 mM KCl, 100  $\mu\text{M}$  DTT and 2  $\mu\text{M}$  GDP, was added to the dried UDP-[ $^{14}\text{C}$ ] Glc. LT (2  $\mu\text{g}/\text{ml}$ ) was then added to start the reaction which was carried out for 1 h at 37°C. The reaction was stopped by adding 5  $\mu\text{l}$  of 2X SDS-sample buffer, boiled, and electrophoresed on a 15% SDS-PAGE. Upon staining with Coomassie blue followed by destaining, the gel was dried and radioactivity was recorded and counted using a phosphoimager system (Molecular Dynamic, Ca.). Glucosylation of HeLa cell lysates by LT was performed as followed; Hela cells ( $5 \times 10^6$ ) were homogenized by 3 cycles of freeze thawing in 200  $\mu\text{l}$  of 50 mM Triethanolamine-HCl buffer pH 7,5 containing 100  $\mu\text{M}$  DTT, 1  $\mu\text{g}/\text{ml}$  leupeptin and pepstatin (glucosylation buffer). Cell lysates (20  $\mu\text{l}$ ) were added to 10  $\mu\text{l}$  of dried UDP-[ $^{14}\text{C}$ ] Glc, and 2  $\mu\text{g}/\text{ml}$  of LT were added to start the enzymatic reaction. After 1 h at 37°C further processing and imaging were done as described above.

### **2.2 "In vivo" glucosylation by LT of small GTP-binding proteins in Rat fibroblasts**

Rat-1 fibroblasts (Rat-1-EJ-Rap2.31.A8) stably transfected with [G12V]Ras and Rap2 (Jimenez, B., et al., Int. J. Cancer 49 (1991) 471-479) were grown in 60mm Petri dishes to a sub-confluent density. LT was added to the cells at the indicated concentration in 5 ml of fresh medium containing 10% FCS. After 2h the cells were removed from the dishes with a rubber policeman and washed in 10 ml PBS followed by centrifugation at low speed. Washing was repeated 5 times to remove residual LT and finally the cell pellets were resuspended in 50  $\mu\text{l}$  of glucosylation buffer. Cells were then lysed by 4 cycles of freeze-thawing. After homogenization, the amount of protein in each cell lysate was estimated. For "in vitro" glucosylation of small GTP-binding proteins with LT, 40  $\mu\text{l}$  of cell lysate was added to 15  $\mu\text{l}$  of dried UDP-[ $^{14}\text{C}$ ] Glc with 5  $\mu\text{g}/\text{l}$  of LT. This mixture was incubated for 1 h at 37°C. Then, 5  $\mu\text{l}$  of each reaction was added to 10  $\mu\text{l}$  of sample buffer, boiled and electrophoresed on a

15% SDS-PAGE. The gel was stained, destained, dried and analyzed for radioactivity by autoradiography.

### **2.3 Localization of the glucosylated amino-acid in H-Ras**

This experiment was performed by microsequencing the radioactively labeled protein. The H-Ras protein (10 µg) was first radioactively glucosylated by LT with 40 µl of dried UDP-[<sup>14</sup>C] Glc (0,8 µCi) for 1h, (reaction conditions as described above). Then, 10 mM unlabeled UDP-Glc was added, the reaction was further incubated for an additional 1 h at 37°C and the proteins were separated on a 12,5% SDS-PAGE. After migration, and staining by amidoblack, the band observed at 21 kDa was cut out from the gel and digested with 1 µg of trypsin in 200 µl of 100 mM Tris-HCl buffer pH 8.8 containing 0,01% Tween 20. The reaction was incubated 18 h at 35°C. The resulting peptides were separated by HPLC using a hydrophobic C18 column with an acetonitrile/trifluoroacetic gradient. Fractions eluted from the column were each analysed for radioactivity. Radioactive peptides were repurified by HPLC, using the C18 column with a sodium acetate buffer pH 6,00 gradient. The eluted peptides were analysed for radioactivity. The radioactive peaks were sequenced with a microsequencer (Applied Biosystem, Ma.) and the product of each Edman degradation cycle was collected and counted for radioactivity.

### **2.4 Immunofluorescence experiments**

Cells grown on coverslips were treated with LT and then fixed with 3% paraformaldehyde for 20 min. After fixation, monolayers were washed three times with PBS and free aldehyde groups were quenched by incubation with 50 mM NH<sub>4</sub>Cl in PBS for 10 min. Cells were permeabilized for 5 min at room temperature in PBS containing 0,2% Triton X100 and then incubated for 30 min at room temperature with the first antibody. Coverslips were then washed extensively with PBS and incubated with the secondary antibodies (Texas red-conjugated sheep anti-mouse (Amersham, UK.)) together with FITC-Phalloidin (Sigma, L'Isle-d'Abeau, France) for 30 min. After 3 washes in PBS, coverslips were mounted in Moviol (Calbiochem-Behring, Germany) and fluorescence observed with a confocal microscope.

### **2.5 MAP-kinases activation**

Experiments examining the effects of LT on epidermal growth factor (EGF)-stimulated MAP-kinases phosphorylation, were performed as follows: Swiss 3T3 cells were cultured according to routine procedures in H21 medium, supplemented with 10% FCS. When the cells reached confluency they were serum-starved overnight in 0.1% FCS. After 3 hours of incubation with LT (1,7 µg/ml) in serum free medium (the activity of LT was monitored by the cytopathogenic

effect on cells), EGF was added (or not) at 50 ng/ml final concentration for 5 min. Cells were then scraped into PAGE sample buffer and 30 µg of total protein, for each experiment, was electrophoresed on 12.5% SDS-PAGE. The gel was blotted to nitrocellulose, and incubated with a monoclonal antibody directed against MAP-kinases (anti ERK1 and ERK2). Immune complexes were detected by horseradish peroxidase-conjugated secondary antibody, followed by the ECL kit (Amersham, UK).

## **2.6 Fluorescence measurements**

LT-catalysed glucosylation of ([Y64W]Ras-GDP) was performed in 50 mM triethanolamine-HCl buffer pH 7.5 containing 140 mM KCl, 1 mM MgCl<sub>2</sub>, 0.1 µM DTT. [Y64W]Ras-GDP (50 µM) was incubated with 100 µM UDP Glc and 2.5 µg/ml LT at 37°C for two hours. Control experiments were performed in the absence of LT.

Guanine nucleotide exchange and GTP hydrolysis of glucosylated versus unmodified [Y64W]Ras (0.5 µM) were measured at 37°C in Hepes 50 mM, pH 7.5, MgCl<sub>2</sub> 1 mM and DTT 1 mM by monitoring tryptophan fluorescence at 340 nm upon excitation at 292 or 300 nm (12). When needed, 2 mM EDTA were added to reduce free magnesium to 0.8 µM.

## **2.7 Cell microinjections**

Diploid Chinese hamster lung fibroblasts (Don cells; ATCC No CCL 16 = Don-wt) and the *C. difficile* toxins A and B resistant mutant of this cell line CdtR-Q (10, 11) here referred to as Don-Q, were grown on 13 mm slides for 48 h. Semiconfluent wildtype and mutant cells were microinjected (Eppendorf microinjector, Germany) with the indicated concentrations of LT, UDP-Glc or anti-LT antibodies with FITC-dextran (Sigma) in calcium-free PBS. Approximately 100 cells were microinjected in each experiment. The cultures were further incubated for 30 min. at 37°C and fixed with 3.7% paraformaldehyde for 10 min. Cells were visualized by phase contrast and fluorescence microscopy.

# **3. Results**

## **3.1 Disruption of actin stress-fibers and formation of filopodia induced in HeLa cells by LT**

The cytopathic effect of *C. sordellii* LT consists of the rounding-up of cell bodies and profound alteration of F-actin containing structures (Popoff, M.R., Infect. Immun. 55 (1987) 35-43; Giry, M., et al., Infect. Immun. 63 (1995) 4063-4071). After a 3 h incubation with 2 µg/ml of LT, HeLa cells became round, displayed F-actin structures rearranged into cell

surface filopodia, and exhibited a loss of actin stress-fibers. Using a polyclonal rabbit antibody which reacts against all known isoforms of the actin bundling protein fimbrin/plastin (Bretscher, A., and Weber, K., Proc. Natl. Acad. Sci. USA 78 (1981) 6849-6853), we observed that fimbrin/plastin was present in LT induced filopodia.

### **3.2 LT catalyzes the UDP-Glc-dependent glucosylation of $M_r$ 21-23 kDa proteins in HeLa cell lysates**

Incubation of HeLa cell lysates with LT in the presence of UDP-[ $^{14}C$ ] Glc, followed by gel electrophoresis of the reaction products, showed that the toxin induced labelling of proteins in the  $M_r$  range of 21-23 kDa (Fig. 1). This reaction could be displaced by adding an excess of non radioactive UDP-Glc but not UDP-glucuronic acid (Fig. 1). No modification of proteins by LT was found with [ $^{14}C$ ] Glc alone.

### **3.3 LT glucosylates $M_r$ 21 kDa proteins "in vivo"**

To demonstrate that small GTP-binding proteins were glucosylated by LT "in vivo", Rat1-EJ-Rap2.31.A8 fibroblasts were incubated with increasing amounts of LT (from 0.005 to 5  $\mu$ g/ml). The highest concentration of toxin caused the characteristic cytopathogenic effect of LT in 100% of the cells within 1 h. All cells were then lysed and the lysates were glucosylated with LT a second time, now "in vitro" in the presence of radioactive UDP-Glc. If LT acts from inside the cell, there should be an inverse correlation between the LT-dose used for "in vivo" pretreatment of cells and the amount of [ $^{14}C$ ]-Glc incorporated into small G-proteins "in vitro". As shown in Fig. 2, the highest rate of glucosylation by LT of a 23 kDa protein was observed in control cells. Two minor bands of 21 and 25 kDa glucosylated by LT, were also noticed in control lysates (Fig. 2). Fig. 2 also demonstrates that a clear decrease to a total absence of labelling of these bands was observed when the cells had been preincubated "in vivo" with increasing concentrations of LT prior to the "in vitro" LT glucosylation. Assuming that LT reacts with small G-proteins, in accordance with its homology to the *C. difficile* toxin B (Green, G.A., et al., Gene 161 (1995) 57-61), this dose-dependent activity of LT suggests that the toxin exerts its action from within the cell.

### **3.4 LT glucosylates Ras, Rap, Ral and Rac small GTP-binding proteins "in vitro"**

Specificity of LT was studied by incubating UDP-[ $^{14}C$ ] Glc and LT with different members of the p21 Ras superfamily of small GTP-binding proteins. As shown in Figs. 3A and 3B, H-Ras, Rap2, Ral and Rac1 were substrates for LT catalysed glucosylation. In contrast, RhoA, Cdc42 and Rab6 were not modified "in vitro" by LT. First, Ral was used as a GST-fusion protein and remained unmodified by our lethal toxin preparation (Fig. 3A). However, when a Ral protein

without protein fused to it was used as a substrate, LT modification of it was positive (Fig. 3B). Finally, no incorporation of glucose catalyzed by LT could be found on Arf1.

### **3.5 LT glucosylates threonine 35 of H-Ras**

To identify the acceptor amino acid glucosylated by LT, H-Ras protein was modified by LT in the presence of UDP-[<sup>14</sup>C] Glc, electrophoresed on SDS-PAGE, digested with trypsin and the resulting peptides were separated, as described in sections 1 and 2. As shown in Fig. 4A, 47 fractions were obtained. The radioactivity was exclusively associated with fractions 39 and 40 (Fig. 4A). As shown in Fig. 4B and 4C, repurification of fraction 39 or 40 gave rise to a major peptide (D for 39 and E for 40) containing the radioactivity and several other small peptides. Peptides D and E were microsequenced and gave exactly the same amino-acid sequence. Each cycle of Edman degradation was collected and counted for radioactivity. The following unambiguous sequence was found for these peptides SALTQLIQNH FVDEYDPTIEDSYR. Cycle 19 corresponding to a threonine gave a very small signal. The small amount of threonine detected in position 19 may be the consequence of the LT catalyzed glucosylation of most of Ras molecules present in the reaction. Decrease or absence of threonine 37 of Rho A in automated amino-acid sequencing, after glucosylation by toxin A or B, has been already reported (Just, I., et al., Nature 375 (1995) 500-503; Just, I., et al., J. Biol. Chem. 270 (1995) 13932-13936). The amino-acid sequence found for both peptides D and E corresponds exactly to a sequence found in the H-Ras protein between amino-acids 17 to 41 (Barbacid, M., Ann. Rev. Biochem. 56 (1987) 779-827). Radioactivity was associated first with cycle 19 and decreased thereafter (Fig. 4E). The rise in radioactivity at cycle 19 establishes threonine 35 (of the H-Ras molecule) as the unique amino-acid glucosylated by LT.

### **3.6 Inhibition of EGF-induced phosphorylation of MAP-kinases in Swiss 3T3 cells by LT**

In serum-starved Swiss 3T3 cells the mitogenic signalling pathway involving tyrosine phosphorylation of growth factor receptors such as EGF receptor and the subsequent Ras dependent activation of MAP-kinases phosphorylation is reduced to a basal level (Cobb, M.H., et al., Cell. Regul. 2 (1991) 965-978). After incubation with EGF, Ras dependent activation of MAP-kinases ERK1 and ERK2 can be followed by a shift in electrophoretic mobility resulting from phosphorylation (de Vries-Smits, A.M.M., Nature 357 (1992) 602-604). If the toxin blocks Ras activity, serum-starved Swiss 3T3 cells incubated with LT before the addition of EGF, should not activate MAP-kinases. As shown in Fig. 5, serum-starved Swiss 3T3 cells incubated with EGF, had MAP-kinases shifted toward higher molecular

weight compared to MAP-kinases of cells not incubated with EGF. In contrast, when serum-starved Swiss 3T3 cells were incubated with LT, prior to incubation with EGF, the growth factor was not able to induce a shift in electrophoretic mobility of the MAP-kinases (Fig. 5).

### 3.7 LT acts in the cytosol by glucosylation

To further substantiate the notion that LT reaches the cytosol and acts by glucosylation of small GTP-binding proteins, a series of microinjection experiments was performed. Don-wt cells were incubated with LT in a medium containing non-immune rabbit serum. The expected characteristic cytopathogenic effect was observed in the whole cell population (Fig. 6A). When rabbit anti-LT antibodies were added to the medium, the same amount of LT as used in Fig. 6A did not affect the cells (Fig. 6B). Drugs blocking the endocytic pathway acidification (Bafilomycin A1, Chloroquine or Monensin) known to prevent many bacterial toxins from penetration into the cytosol (Sandvig, K., et al., Biochem Soc. Transact. 20 (1992) 724-727), blocked the activity of LT on cells. When Don-wt cells in medium containing anti-LT antibodies were microinjected with LT they rapidly exhibited the cytopathogenic effect characteristic for LT (Figs. 6C and D). Successful microinjection was monitored by a yellow-green fluorescence of fluorescein-dextran added to the solutions microinjected (see Materials and Methods). This showed that LT can exert its activity from the cytosol.

To demonstrate that the activity of LT is mediated through glucosylation (of G-proteins) advantage was taken of a mutant Don cell (Don-Q). This cell has a low content of UDP-Glc which renders it resistant to the glucosylating toxins A and B of *C. difficile* and also to LT (Chaves-Olarte, E., et al., J. Biol. Chem. (1996), in press). Don-Q cells were incubated with LT, followed by microinjection of UDP-Glc into some of them (those lighting up under fluorescence microscopy). As shown in Figs. 6E and F, only cells which were microinjected with UDP-Glc exhibited the characteristic cytopathogenic effect of the toxin, suggesting that the toxin and the cofactor act at the same side of the cell membrane. The specificity of the effect was confirmed by microinjecting instead of UDP-Glc, UDP-Gal or UDP-GlcUA (100 mM) in cells similarly treated with LT. Neither of the additionally used activated sugars promoted any cytopathogenic effect. Finally, none of the three UDP-sugars used in this study had any effect if the cells were not pretreated with toxin. Knowing that our rabbit anti-LT serum neutralised the toxin, Don-wt cells were microinjected with this serum and then incubated with LT added to the medium. As shown in Figs. 6G and H, microinjection of anti-LT antibodies protected against LT, clearly indicating that the neutralising antibody and the toxin meet each other in the cytosol. Accordingly, cells not injected exhibited the cytopathogenic effect typical of LT (Figs. 6G and H), as did cells microinjected with non-



immune rabbit serum. The experiments shown in Fig. 6 together with those presented in Fig. 2, show that LT acts from the cytosol by glucosylating small GTP-binding proteins, using UDP-Glc as a cofactor.

### **3.8 LT-glucosylation of Ras enhances GTP dissociation rate and reduces GTP hydrolysis of the GTP-binding protein.**

The effects of LT glucosylation on the intrinsic properties of Ras was studied using the [Y64W]Ras mutant. This mutant has the same intrinsic biochemical properties as wild-type Ras, but its activation-deactivation cycle can be followed in real time by monitoring changes in the fluorescence of tryptophan residue 64 (Antonny, B., et al., *Biochemistry* 30 (1991) 8287-8295). In Fig. 7A, [Y64W]Ras-GDP, glucosylated or not, was first activated by the addition of GTP. After several minutes, the protein was converted again to the GDP-bound form by addition of a large excess of GDP. This experiment was performed at a low magnesium concentration, in order to favor the dissociation of the bound nucleotide (the rate limiting step of nucleotide exchange) and to prevent GTP hydrolysis. Similar fluorescence changes were observed for the unglucosylated and glucosylated forms of Ras (Fig. 7A). Indeed binding of GTP in place of GDP induced a decrease in fluorescence and conversely binding of GDP in place of GTP, an increase in fluorescence. Upon GTP addition, the time course of the fluorescence decrease was similar for the two forms of Ras, indicating that glucosylation did not greatly modify the GDP dissociation rate. In contrast, the increase in fluorescence by GDP addition was four time faster for the glucosylated Ras than for the unmodified Ras (Fig. 7A). This result demonstrates that glucosylation weakened GTP binding in the nucleotide site of Ras, by accelerating its dissociation rate. Similar effects of glucosylation were observed for the dissociation rate of GTP $\gamma$ S, either at low (1  $\mu$ M) or high (1 mM) magnesium concentration.

The effect of glucosylation on GTP hydrolysis by Ras is shown in Fig. 7B. [Y64W]Ras-GDP was incubated with GTP at 1 mM magnesium. Activation was triggered by the addition of 2 mM EDTA which reduced the free magnesium concentration below 1  $\mu$ M. The first instantaneous fluorescence decrease reflected the dissociation of magnesium from [Y64W]Ras-GDP, whereas the slower fluorescence decrease reflected (as in Fig. 7A) the exchange of GTP for GDP. After completion of GDP/GTP exchange, magnesium was added back to the reaction (1 mM free magnesium). Due to the intrinsic GTPase activity of the protein, the fluorescence of the unmodified form of Ras slowly increased towards the level of fluorescence initially observed for Ras-GDP (Fig. 7B). In the case of the glucosylated form of Ras a much slower kinetics of GTPase activity was observed. Indeed, upon glucosylation of threonine 35 Ras had a four times slower intrinsic GTPase activity (Fig. 7B).

Glucosylation of [Y64W]Ras by LT slightly modified the fluorescence of the protein. As compared to unmodified [Y64W]Ras, LT glucosylated [Y64W]Ras exhibited, on one hand, a larger absolute fluorescence level and, on the other hand, a smaller fluorescence change upon GDP/GTP exchange or GTP hydrolysis (Figs. 7A and 7B). Therefore, we looked for a fluorescence signal that could correlate with the glucosylation of the protein. When [Y64W]Ras-GDP was incubated with LT and UDP-Glc, fluorescence was enhanced by 2 % within 2 hours (Fig. 7C). Since this signal required both LT and UDP-Glc, it certainly reflects the time course of UDP-Glc incorporation.

#### **4. Production of immunotoxins**

Immunotoxins combine three parts: (1) a targeting device, specific for receptor molecules on the cell to be treated, (2) a translocation domain which enables the catalytic part (3) of the compound to cross the cell membrane.

##### **The catalytic domain**

Several catalytic domains of bacterial toxins have been used for constructing immunotoxins. The catalytic domain of such an immunotoxin hits an intracellular target of major importance for the cell, to be active in minimal amounts (ideally one molecule of enzyme per cell) finally blocking cell proliferation.

Targets may be the translation machinery and, our novel approach, reactions related to cell proliferation (such as transcription/signalling processes). Diphtheria toxin and *Pseudomonas* exotoxin A modify elongation factor (EF-2), thus blocking translation of mRNA into protein. LT of *C. sordellii* carries a novel catalytic principle in two respects: It is a glucosyltransferase, and it modifies the signal transducing small G-protein Ras, thus interfering with cell proliferation signals.

Diphtheria toxin and the *P. exotoxin A* have both successfully been used for constructing immunotoxins. Basically, their catalytic domain is amplified from the total DNA sequence by polymerase chain reaction (PCR) and then fused "in frame" to a targeting translocation device. The catalytic domain of LT is contained within the N-terminal 1020 amino acids of the molecule. Oligonucleotides (primers BCS1C (SEQ ID NO:1) and BCD2N (SEQ ID NO:2)) serve as 5'- and 3'-end primers for PCR amplification, respectively. These primers are elongated at both ends by small oligonucleotides of 8-12 base pair length which contain restriction sites allowing the in-frame cloning into the acceptor construct. The latter contains

the targeting translocation device. Such acceptor constructs are the cognate sequence of diphtheria toxin or of exotoxin A or parts thereof. Cloning is in frame, such that a fusion protein is produced in *E. coli* that harbors both the catalytic glucosyltransferase and the targeting translocation device in a functional manner.

Such an immunotoxin has the target Ras inside the cell, and this G-protein is inactivated by adding a glucose moiety into the effector domain at position threonine-35.

The catalytic domain is a defined N-terminal segment of LT which may replace catalytic domains in any other known immunotoxin such as the ADP ribosyltransferase catalytic domains of DT and ExoA. Replacing these catalytic segments can be achieved by either cutting the segment out of the DNA construct with restriction enzymes followed by integration of the appropriate LT catalytic domain, or by combined, separate PCR amplification of both the LT catalytic fragment and the targeting translocation device and then ligating these into a vector system finally allowing expression of the combined construct.

#### **Targeting translocation device (T-T device)**

The targeting translocation device is taken from existing immunotoxin constructs such as immunotoxins derived from Diphtheria toxin or Pseudomonas exotoxin. The T-T device has the following properties: Firstly, it binds specifically to cells, differentiating between normal and tumor cells because of differential expression of the appropriate surface structure (receptor of hormones, cytokines, antigenic structure recognized by an antibody). Secondly, it mediates the transmembranal passage of the catalytic domain into the cytosol. Any such device can be used for targeting and translocation of the catalytic glucosyltransferase domain of LT into the cell, where the toxin acts.

In case of taking the translocation domain of LT (nucleotide sequences coding for approximately amino acids 1021-1700), the catalytic translocation domains of LT (nucleotide sequences coding for approximately amino acids 1-1700) are PCR-amplified (primers BCD2C (SEQ ID NO:3) and BCS3N (SEQ ID NO:4) for the translocation domain, or BCS1C and BCS3N for the catalytic translocation domains) allowing to obtain a combined catalytic translocation part in one segment. The targeting structure is then taken from the above mentioned sources, like hormones, growth factors, etc.

The immunotoxins may be produced in *E. coli* as fusion proteins or as recombinant *E. coli* proteins in separate parts, followed by chemically combining the different segments in the "test tube", both according to methods described and known.

PCR primers of the catalytic domain are BCS1C (SEQ ID NO:1) and BCD2N (SEQ ID NO:2).

PCR primers of the translocation domain are BCD2C (SEQ ID NO:3) and BCS3N (SEQ ID NO:4).

As PCR primers for the catalytic and translocation domains, BCS1C and BCS3N are used, as a primer pair.

#### List of References

- Allured, V.S., et al., Proc. Natl. Acad. Sci. USA 83 (1986) 1320-1324  
Antonny, B., et al., Biochemistry 30 (1991) 8287-8295  
Arseculeratne, S.N., et al., J. Med. Microbiol. 2 (1969) 37-53  
Atlas, I., et al., Cancer Res. 52 (1992) 3335-3339  
Barbacid, M., Ann. Rev. Biochem. 56 (1987) 779-827  
Batra, J.K., et al., Proc. Natl. Acad. Sci. USA 89 (1992) 5867-5871  
Bette, P., et al., Toxicon 29 (1991) 877-887  
Bretscher, A., and Weber, K., Proc. Natl. Acad. Sci. USA 78 (1981) 6849-6853  
Brinkmann et al., Proc. Natl. Acad. Sci. USA 90 (1993) 7538 - 7542  
Brinkmann, et al., Proc. Natl. Acad. Sci. USA 89 (1992) 3075 - 3079  
Carrel, S., et al., Eur.J Immunol., 16 (1986) 649-652  
Chaves-Olarte, E., et al., J. Biol. Chem. (1996), in press  
Choe, S., et al., Nature 357 (1992) 216-222  
Cobb, M.H., et al., Cell. Regul. 2 (1991) 965-978  
de Vries-Smits, A.M.M., Nature 357 (1992) 602-604  
EMBL DataBank Accession No. X82638  
EP-B 0 194 276  
Giry, M., et al., Infect. Immun. 63 (1995) 4063-4071  
Goldenberg, et al., J. Clin. Oncology 9 (1991) 548 - 568  
Green, G.A., et al., Gene 161 (1995) 57-61  
Hall, A., Ann. Rev. Cell. Biol. 10 (1994) 31-34

- Harwerth, I.-M., et al., J. Biol. Chem. 21 (1992) 15160-15167
- Herrmann, C., et al., J. Biol. Chem. 270 (1995) 2901-2905
- Humphrey, P.A., et al., Proc. Natl. Acad. Sci. U S A 87 (1990) 4207-4211
- Jimenez, B., et al., Int. J. Cancer 49 (1991) 471-479
- John, J., et al., J. Biol. Chem. 268 (1993) 923-929
- Just, I., et al., J. Biol. Chem. 269 (1994) 10706-10712
- Just, I., et al., J. Biol. Chem. 270 (1995) 13932-13936
- Just, I., et al., J. Clin. Invest. 95 (1995) 1026-1031
- Just, I., et al., Nature 375 (1995) 500-503
- Kalofonos, H.P., et al., J. Nucl. Med. 30 (1989) 1636-1645
- Kaminski, et al., New England Journal of Medicine 329 (1993) 459 - 465
- Kasprzyk, P.G., et al., Cancer Res. 52 (1992) 2771-2776
- Kohl, N.E., et al., Science 260 (1993) 1934-1937
- Levitzky, A., Euro. J. Biochem. 226 (1994) 1-13
- Lyerly, D.M., et al., Clin. Microbiol. Rev. 1 (1988) 1-18
- Madaule, P., and Axel, R., Cell 41 (1985) 31-40
- Martinez, R.D., and Wilkins, T.D., J. Med. Microbiol. 36 (1992) 30-32
- Monoclonal Antibodies in Clinical Medicine, ed. McMichael, A.J., and Fabre, J.W., Academic Press, London (1982) 168-192
- Montecucco, C., and Schiava, G., Trends Biochem. Sci. 18 (1993) 324-326
- Nassar, N., et al., Nature 375 (1995) 554-560
- Nobes, C.D., and Hall, A., Cell 81 (1995) 53-62
- Pai, E.F., et al., EMBO J. 9 (1990) 2351-2359
- Popoff, M.R., Infect. Immun. 55 (1987) 35-43
- Press, et al., New England Journal of Medicine 329 (1993) 1219 - 1224
- Press, O.W., et al., J. Clin. Onc. 7 (1989) 1027-1038
- Prior, T.I., et al., Biochemistry 31 (1992) 3555-3559
- Razakis-Adocke, M., et al., Nature 363 (1993) 83-85
- Reinherz, E.L., et al., Immunol Rev. 74 (1983) 83-112
- Ridley, A.J., et al., Cell 70 (1992) 401-410
- Sandvig, K., et al., Biochem Soc. Transact. 20 (1992) 724-727
- Segal, M., et al., Proc. Natl. Acad. Sci. USA 90 (1993) 5564-5568
- Shirasawa et al., Science 260 (1993) 85-88
- Sullivan, N.M., et al., Infect. Immun. 35 (1982) 1032-1040
- US Patent No. 4,947,778
- US Patent No. 5,091,513

US Patent No. 5,132,405

von Eichel-Streiber, C., et al., Microbiol. Pathogenesis 2 (1987) 307-318

von Eichel-Streiber, C., et al., Mol. Microbiol. 17 (1995) 313-321

von Eichel-Streiber, C., et al., Trends in Microbiology 4 (October 1996) 375-382

Wels, W., et al., Cancer Res. 52 (1992) 6310-6317

Welt, S., et al., J. Clin. Oncol. 8 (1990) 1894-1906

White, M.A., et al., Cell 80 (1995) 533-541

WO 88/01649

WO 88/09344

WO 94/04696

WO 94/22476

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: BOEHRINGER MANNHEIM GMBH
- (B) STREET: Sandhofer Str. 116
- (C) CITY: Mannheim
- (E) COUNTRY: Germany
- (F) POSTAL CODE (ZIP): D-68305
- (G) TELEPHONE: 08856/60-3446
- (H) TELEFAX: 08856/60-3451

(ii) TITLE OF INVENTION: Method of inactivation of P21 Ras and agents therefor

(iii) NUMBER OF SEQUENCES: 4

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30B (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 31 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "primer BCS1C"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GGGGAATTTT AATGAGCTCA GTTAACAAAG C

31

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "primer BCD2N"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

TTCAGATAAT GTAGGTACCA AGTCTATAG

29

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 29 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "primer BCD2C"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CTATAGACTT GGTACCTACA TTATCTGAA

29

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 28 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: other nucleic acid

(A) DESCRIPTION: /desc = "primer BCS3N"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

TATTAACGTG GGCCCAATAT ATGTCTAC

28



### **Patent Claims**

1. Method of treating a patient with a disorder, characterized by an activating mutation in the Ras proto-oncogene, comprising contacting cells of said patient with a protein having the toxic activity of Clostridium sordellii toxin LT under conditions favoring inactivating of Ras by glucosylation of Ras subfamily proteins.
2. The method according to claim 1, characterized in that the disorder is pancreas or colon cancer.
3. The method according to claim 1 wherein said protein is an immunotoxin.
4. The method according to claims 1 to 3 wherein said immunotoxin contains a first part, a second part, and a third part, connected by covalent bonds:
  - (i) the first part including a target cell specific binding domain, which domain is able to cause the immunotoxin to bind to said patient's cell;
  - (ii) the second part including a translocation domain of a protein, which domain is capable of translocating the third part across the cytoplasmic membrane of the cell, and
  - (iii) the third part including a polypeptide with the toxic activity of the catalytic domain of toxin LT from Clostridium sordellii LT.
5. The method according to claims 4, characterized in that the target cell specific binding domain is an antibody or an active fragment thereof.
6. The method according to claim 5 wherein the antibody or active fragment thereof specifically binds to tumor cells.
7. A composition useful in treating a pathological condition, characterized by activation of Ras proto-oncoproteins, comprising a first part, a second part, and a third part, connected by covalent bonds:
  - (i) the first part including a target cell specific binding domain, which domain is able to cause the immunotoxin to bind to said patient's cell;

- (ii) the second part including a translocation domain of a protein, which domain is capable of translocating the third part across the cytoplasmic membrane of the cell, and
- (iii) the third part including a polypeptide with the toxic activity of the catalytic domain of toxin LT from *Clostridium sordellii* LT,


and a pharmaceutically acceptable carrier.

8. An immunotoxin which contains a first part, a second part, and a third part, connected by covalent bonds:
  - (i) the first part including a target cell specific binding domain, which domain is able to cause the immunotoxin to bind to said patient's cell;
  - (ii) the second part including a translocation domain of a protein, which domain is capable of translocating the third part across the cytoplasmic membrane of the cell, and
  - (iii) the third part including a polypeptide with the toxic activity of the catalytic domain of toxin LT from *Clostridium sordellii* LT.
9. An immunotoxin according to claim 8, characterized in that the target cell specific binding domain is an antibody or an active fragment thereof.
10. Method of manufacturing a therapeutic agent, characterized by combining a therapeutically useful amount of an immunotoxin according to claim 8 with a therapeutically acceptable adjuvant or carrier.
11. Method of treating a patient with a disorder, characterized by an activating mutation in the Ras proto-oncogene, comprising contacting cells of said patient with a retroviral or non-viral vector utilizable for transformation of tumor cells, which mediates expression of the aminoterminal 1020 amino acids, or a fragment thereof with preserved glucosyltransferase activity.


**Abstract**

The invention comprises a method of treating a patient with a disorder, characterized by an activating mutation in the Ras proto-oncogene, comprising contacting cells of said patient with a protein having the toxic activity of *Clostridium sordellii* toxin LT under conditions favoring inactivating of Ras by glucosylation of Ras' threonine 35 in said cell. Said protein preferably is an immunotoxin which contains as a toxic domain the catalytic domain of toxin LT.



**Fig. 1**



**Fig. 2**



H-Ras Rap2 Rac1 Cdc42 RhoA Rab6 Ral-GST Rac1-GST Fig. 3A



**Fig. 3B**







Fig. 4-1




**D**



Radioactivity in amino-acids sequenced from peptides D and E




**Fig. 4-2**



Radioactivity in peptides purified from fraction 39



Radioactivity in peptides purified from fraction 40





**Fig. 5**




Fig. 6







Fig. 7

